Kunmai Medical Secures Global First Certification for Helium-Free Quantum MEG System, Filling Domestic Technology Gap

Magnetoencephalographyis a brain functional imaging technology that enables real-time detection of magnetic fields generated by neural electrical activity in the brain, featuringNon-invasive, Radiation-freecharacteristics, andThe signal features both high temporal resolution and high spatial resolution.. Therefore, magnetoencephalography (MEG) has been widely used for the auxiliary localization and diagnostic assessment of epileptic foci and functional brain areas prior to neurosurgery, and it has been incorporated into clinical application guidelines and expert consensus statements both domestically and internationally. Furthermore, MEG plays a significant role in research on the early diagnosis and assessment of major brain disorders, including depression, schizophrenia, traumatic brain injury, and Alzheimer’s disease.

Previously, imported magnetoencephalography (MEG) devices widely used in the industry relied on superconducting technology. They were expensive and bulky, requiring liquid helium and magnetically shielded rooms for operation, along with complex procedures. To address these market pain points,QUANMAG(hereinafter referred to as “QUANMAG”) independently developedCryogen-Free Quantum MagnetoencephalographyIncludes items that can beArray of Quantum Weak Magnetic Field Sensors Operating at Room TemperatureandTechnical modules such as high-flexibility, high-performance magnetic shielding devices, thereby eliminating the device's reliance on liquid helium and significantly simplifying the installation process. This enhances the operational efficiency of magnetoencephalography (MEG), lowers the threshold for hospital adoption, expands its clinical applicability, and reduces the burden on patients.Solved the problems of high cost and limited clinical application of imported superconducting magnetoencephalography.

In May this year, QUANMAG’s independently developed innovative medical device, the “Magnetoencephalography (MEG) System,” received approval from the National Medical Products Administration (NMPA) for market launch (Registration Certificate No.: Jing Xie Zhu Zhun 20242070274), becomingThe World’s First Clinically Approved Liquid-Helium-Free Magnetoencephalography (MEG) Device Based on Atomic Magnetometer (Also Known as Optically Pumped Magnetometer, i.e., OPM) Technology. This product is the result of years of effort by QUANMAG's core teamAccumulated R&D Achievements Over the Past Decade, and also represents the clinical application translation of the Major Instrument Development Project funded by the National Natural Science Foundation of China, as well as the Disruptive Technology R&D and Achievement Transformation Project in Zhongguancun, Beijing.

On Monday, June 17, at 19:30, the 68th session of VCBeat Select New Product Review will feature Wu Jiangfen, Marketing Director of QUANMAG, and Song Yizheng, Operations Director of QUANMAG Medical, who will present“The World’s First Cryogen-Free Quantum Magnetoencephalography System to Gain Clinical Approval”Product Introduction.

The image shows QUANMAG’s independently developed innovative medical device: the liquid-helium-free quantum “Magnetoencephalography (MEG) System.”

QUANMAG’s Liquid-Helium-Free Quantum Magnetoencephalography CanNon-invasive in vitro recording of brain neural activity information, enabling auxiliary localization and diagnostic evaluation of lesions and functional brain areas in functional brain disorders, exemplified by epilepsy.

This product featuresOptically Pumped Magnetometer (OPM)as the core, helium-free, enablingDetection at Room Temperature, compared to traditional superconducting magnetoencephalography, OPM detectorsCan be placed close to the scalp, thereby acquiring stronger magnetoencephalographic (MEG) signals. By leveraging advanced magnetic shielding and magnetic imaging technologies, the system eliminates the need for constructing a dedicated magnetically shielded room, offering more cost-effective and flexible installation with higher clinical feasibility. Moreover,Lower Maintenance Costs, enabling more flexible and diverse application scenarios.

Depression, schizophrenia, traumatic brain injury, Alzheimer's disease, Parkinson's disease, etc.

Identifying stimulable and treatable targets via magnetoencephalography to establish a closed-loop diagnostic and therapeutic system

Cryogen-Free Magnetoencephalography Based on OPM Technology Provides a New Pathway for Non-Invasive Brain-Computer Interfaces at the Whole-Brain Scale, Facilitating Breakthroughs in Neural Encoding/Decoding and Brain-Controlled Devices

Scan the QR code on the poster to add the assistant and reserve a spot for the live broadcast

Wu Jiangfen

Marketing Director, QUANMAG

Ph.D. in Biomedical Engineering from Peking University; formerly Senior Application Specialist at a multinational medical imaging company and Director of Clinical Translation at a leading medical AI startup; with extensive experience in the commercialization of innovative medical imaging products.

Song Yizheng

Operations Director, QUANMAG

Sichuan University, majoring in Nuclear Physics; formerly employed at the Ministry of Ecology and Environment; possesses extensive experience in the industrialization of scientific and technological achievements; currently responsible for the company’s daily operations and financing activities.

QUANMAG is a technology enterprise centered on ultra-sensitive weak magnetic detection and imaging, dedicated to the independent research and development of liquid-helium-free quantum magnetoencephalography (MEG). This liquid-helium-free quantum MEG enables non-invasive, radiation-free millisecond-level detection of neural activity and millimeter-level localization of lesions and functional areas, ensuring precise diagnosis and protection of each patient’s neurological function!

As a technological innovator in magnetoencephalography (MEG), the company has leveraged ten years of R&D accumulation to build a helium-free quantum MEG closed-loop technology platform centered on its independently developed next-generation optically pumped magnetometers (OPMs). This platform integrates precision weak magnetic field detection, high-efficiency magnetic shielding, and high-resolution magnetic inversion. The company has spearheaded the first domestic patent portfolio for quantum MEG and published the inaugural findings on quantum-sensing-based MEG detection. Currently, the company has secured the world’s first clinical approval for a helium-free MEG system, with its product receiving certification as an innovative medical device. Achieving original R&D and manufacturing of MEG systems, the company possesses a complete industrial chain covering production, installation, and commissioning. Its products have been deployed at West China Hospital of Sichuan University, Sanbo Brain Hospital of Capital Medical University, and the Beijing Huairou Multi-modal Cross-scale Biomedical Imaging Facility Platform.

Leveraging early-stage R&D collaboration with Peking University and support from the National Major Scientific Instrument Special Project of the National Natural Science Foundation of China, the company has, over nearly a decade of development, established a portfolio of dozens of intellectual property rights. It has been recognized as a National High-Tech Enterprise, a Beijing “Innovative” Small and Medium-sized Enterprise (SME), a Beijing “Specialized, Refined, Differential, and Innovative” SME, and a Beijing Intellectual Property Pilot Unit. Furthermore, the company has achieved outstanding results in numerous competitions, including the Zhongguancun International Frontier Technology Innovation Competition, the HICOOL Global Entrepreneurship Competition, the China International “Internet+” Innovation and Entrepreneurship Competition, and the Medical Technology Innovation Challenge.

“Artery Select New Product Showcase” is a live-streaming program under the “Artery Select” brand, dedicated to supporting healthcare companies in launching innovative products. The program’s mission is to empower every milestone launch of medical innovation products.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively consult the assistant)